On July 10th, Wang Yutian, Fellow of The Royal Society of Canada (the Academy of Sciences of Canada), signed a cooperation agreement with Lanpu Biological Technology Co., Ltd. and Beijing UnderProved Medical Technology Co., Ltd. to establish Changchun Lanpu Medical Technology Co., Ltd. The signing ceremony was held in Shangri-La Hotel, Changchun.

（Academician Wang Yutian and General Manager Sui Chun of Lanpu Bological Technology Co., Ltd. sign the cooperation agreement）

Wang Haiying, Vice Mayor of Changchun, Li Weibin, Director of Changchun Industry and Information Technology Bureau, Wen Guijun, Deputy Director of Changchun Healthcare Committee, Jiang Bo, Deputy Director of Changchun Municipal People's Government Cooperation and Exchange Office, Xue Chunlong, Deputy Director of Changchun New District Management Committee, and other leaders attended the event.

（Academician Wang Yutian）

Profile of Wang Yutian, Fellow of The Royal Society of Canada (the Academy of Sciences of Canada)

Academician Wang Yutian’s team is renowned as one of the world's leading scientific research teams in the field of cranial nerve research and has published over 160 articles in the field of medicine and neuroscience. Academician Wang Yutian has won many awards granted by the Canadian Federal and Provincial Governments. He was commended twice as the international research scholar by Howard Hughes Medical College (HHMI) in 2002 and 2006. In 2006, he was elected as a fellow of The Royal Society of Canada (the Academy of Sciences of Canada). In 2014, he was elected as an overseas expert and advisory committee member of the Overseas Chinese Affairs Office of the State Council of the People’s Republic of China. Academician Wang Yutian also serves as an overseas accreditation expert of the Chinese Academy of Sciences, the Natural Science Foundation of China, and Changjiang Scholars.

Founded in 2018, Lanpu Biotechnology Co., Ltd. is the upstream holding company of Changchun Lanke Medical Technology Co., Ltd. and Jilin Landing Technology Co., Ltd. It specializes in molecule polypeptide engineering and focuses on biomedical R&D, research result transfer, and production.

While actively pursuing product development, Lanpu Biotechnology Co., Ltd. has established a long-term strategic cooperation with Beijing UnderProved Medical Technology Co., Ltd. The two companies have also established close cooperation with universities and hospitals in scientific research and academic fields, and have helped in transferring scientific research results into practical and marketable applications, thereby helping research organizations to focus on their core competency of innovation.

Beijing UnderProved Medical Technology Co., Ltd. was established in 2010 by a team of founders with a strong professional medical background. The company focuses on research and development of medical technology, management, and market transformation. In the past nine years, it has been deeply involved in the field of dermatology, and has joined hands with authoritative experts in medicine, pharmacology, bioengineering, clinical medicine, traditional Chinese medicine, botany, and other disciplines to create a professional consultant team that creates and develops medical technologies that are accessible to a wide range of people.

The partner brands of Beijing UnderProved Medical Technology Co., Ltd. and Lanpu Biotechnology Co., Ltd. are as follows:

Lanpu Medical Research Co., Ltd. is all set to develop a new type of molecule polypeptide that can control adipocyte division and reduce oil secretion.